Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants (NCT02573012), a randomized phase 4 study. The primary outcome is Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization.

2. Clinical Question

3. Trial Design

The registry classifies this as a Phase 4, randomized, double-blind, parallel-group, placebo-controlled interventional study. The study description calls it a Phase IIIb/IV trial and describes it as international and multicentre. Enrollment was 314. Participants with rheumatoid arthritis and stable low disease activity while receiving tocilizumab were assigned to a prednisone-tapering strategy or a constant-dose strategy.

Both groups received tocilizumab at 162 milligram subcutaneously once a week. In the constant-dose group, prednisone was 5 milligram per day for 24 weeks, or participants received matching oral placebo as described in the arm information. In the tapering group, prednisone started at 5 milligram per day with 1 mg decrements every 4 weeks, or participants received matching oral placebo. The registry describes the prednisone strategies as double-blinded.

The primary outcome was change in DAS28-ESR from baseline to Week 24 after randomization. The primary endpoint is continuous: the record reports least-squares means and 95% confidence intervals for each arm, as well as an ANCOVA comparison. Secondary measures include treatment success, flare occurrence, time to first flare, and use of flare-rescue medication. The registry record does not report details of the randomization sequence, concealment procedures, site locations, or the operational definition of treatment success. These design details should not be inferred from the randomized, double-blind labels alone.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 314 participants were enrolled in the study; 55 participants discontinued the study prior to randomization; 259 participants were randomized.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization, measured over Baseline to Week 24.

The primary endpoint is change from baseline to Week 24 in the Disease Activity Score in 28 joints using erythrocyte sedimentation rate, or DAS28-ESR. The score combines tender and swollen joint counts across 28 joints, ESR, and the participant’s global assessment of disease activity. The registry describes the score as ranging from 0 to 10, with higher scores representing higher disease activity. A positive change indicates worsening; a negative change indicates improvement.

This composite is used to summarize several aspects of rheumatoid arthritis activity in a single measure. Its components capture joint findings, an inflammatory marker, and the participant’s overall assessment, rather than relying on one feature alone. The record specifies that the global assessment uses a 100-millimeter visual analog scale and describes how an ESR of 0 mm/hr was handled in the score calculation.

Change from baseline focuses the comparison on how the score shifted during follow-up, rather than only on the Week 24 score. The reported arm estimates are least-squares means, with 95% confidence intervals. The registry record does not report the specific covariates used in the ANCOVA model or further details about how the analysis handled missing endpoint measurements.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a least-squares mean represent?

The primary arm estimates are least-squares means, a model-based way to summarize the expected outcome in each group. They are not necessarily the same as simple arithmetic averages of the observed participant values. In general, least-squares means depend on the statistical model and any covariates included in it. The registry names ANCOVA for the between-group primary analysis but does not report the covariates or other model specifications. Therefore, the adjusted estimates can be described as reported without assuming exactly how the adjustment was performed.

The posted arm-level estimates are 0.538 for tapering and -0.075 for constant-dose prednisone. Their confidence intervals describe uncertainty in those estimates. The sponsor’s ANCOVA contrast is 0.613. That contrast is the primary between-group result; it should not be recreated by subtracting rounded arm estimates, since the model-based comparison need not equal a calculation from rounded summaries.

How should the confidence interval be read?

In general, a confidence interval describes the precision of an estimate under the assumptions of the analysis. A narrower interval indicates greater precision than a wider interval on the same scale. For the primary comparison, the 95% confidence interval runs from 0.346 to 0.879. Because the interval is entirely positive, the reported range is consistent with a larger average increase in DAS28-ESR under tapering than under constant-dose prednisone. The interval does not cover every source of uncertainty: it does not account for unreported modeling choices, missing-data procedures, or limitations in the population studied.

A confidence interval is not a prediction interval for individual participants and does not say that a particular participant’s change will fall inside it. It also does not, by itself, define whether the difference is clinically important. The registry record does not give a clinical-importance threshold for this contrast.

What does the p-value add?

In general, a p-value measures how unusual data at least as inconsistent with a specified null hypothesis would be if that null hypothesis and the analysis assumptions were true. It is not the probability that the null hypothesis is true, and it is not a measure of the size or importance of an effect. The primary reported p-value is 0.001 for the ANCOVA comparison. It should be interpreted together with the estimated contrast and its confidence interval, rather than as a stand-alone conclusion.

The registry reports an analysis of superiority. That label identifies the type of comparison, but the record does not provide the full statistical analysis plan, the exact hypothesis-testing framework, or any prespecified decision thresholds beyond the reported results. Those details are not reported in the registry record.

What is the role of the secondary recalculations?

For posted binary secondary outcomes, the recalculated comparisons use the summary event counts and denominators to produce unadjusted measures. For treatment success, the registry also reports logistic-regression and Cochran-Mantel-Haenszel analyses. The reported odds ratio is 0.50 with a 95% confidence interval from 0.285 to 0.889 and p = 0.018; the reported relative risk is 0.833 with a 95% confidence interval from 0.714 to 0.972 and p = 0.021. These sponsor-reported results are model-based or method-specific and are not interchangeable with an unadjusted risk difference.

For other secondary comparisons, the recalculated estimates are simple unadjusted comparisons from posted summary statistics. They may not match a sponsor analysis that uses covariate adjustment or a different model. For time to first RA flare, the record posts arm means and standard deviations and a recalculated mean difference. The endpoint is therefore presented as a mean in the registry record; it should not be assumed to be a survival-model estimate just because its title refers to time to an event.

What do the sample-size illustrations mean?

In general, a sample-size calculation describes a hypothetical design under specified assumptions. The registry’s planning illustrations use a two-sided significance level of 0.05, equal allocation, and a normal approximation. The effect to detect is set to the stated fraction of the observed effect. These are planning illustrations based on observed effects, not observed power and not evidence that the trial was originally designed using those assumptions. The registry record does not report the original sample-size justification or its assumptions. Values for time-to-event planning are described as total event counts using the Schoenfeld method; the other planning values are participants per arm.

Planning estimates depend on the chosen effect, outcome variability or event frequency, analysis method, and assumptions about follow-up and missing data. Smaller target effects generally require larger studies under otherwise comparable assumptions; that is a general statistical principle, not a separate result from this trial. The illustrations should not be read as a retrospective measure of whether the trial was adequately powered.

10. Analyses Reported by the Sponsor

The sponsor’s primary analysis is an ANCOVA comparison of least-squares means. It reports a difference of 0.613, a 95% confidence interval from 0.346 to 0.879, and p = 0.001. This is the registry’s stated between-group analysis for the primary endpoint. The arm-level changes are 0.538 for prednisone tapering and -0.075 for constant-dose prednisone, with their respective 95% confidence intervals also reported.

No independent recalculated two-arm comparison is available for this continuous primary endpoint from the posted summary statistics. Accordingly, the sponsor’s ANCOVA result is the appropriate primary comparison to cite; it should not be replaced by a subtraction of the rounded arm estimates or by an unadjusted calculation that the posted summaries do not support.

For treatment success, the sponsor reports an odds ratio of 0.50 with a 95% confidence interval from 0.285 to 0.889 and p = 0.018, and a relative risk of 0.833 with a 95% confidence interval from 0.714 to 0.972 and p = 0.021. The unadjusted recalculated comparison is a different estimand and method, so its p-value need not equal either sponsor-reported p-value. The registry record does not report enough detail to determine all differences in adjustment or model specification.

11. Multiplicity, Missing Data and Analysis Populations

The registry record reports one primary outcome and multiple secondary outcomes, but it does not report a multiplicity strategy. Specifically, no adjustment method, testing hierarchy, allocation of type I error across outcomes, or distinction between confirmatory and exploratory secondary hypotheses is reported in the registry record. Without that information, the secondary p-values should not be interpreted as if each were the sole prespecified test. This matters because examining many outcomes can increase the chance of at least one apparently persuasive result by chance.

The record reports selected analysis methods, including ANCOVA for the primary endpoint and logistic regression and Cochran-Mantel-Haenszel methods for treatment success. It does not report the complete statistical analysis plan, all model specifications, or whether any planned interim analyses were conducted. Those matters are not reported in the registry record and should not be inferred from the results posted.

Details about missing data are also not reported in the registry record. The available information does not specify how missing Week 24 measurements were handled, whether imputation was used, how participants who discontinued or deviated from the assigned prednisone strategy were analyzed, or which analysis population was used for each outcome. The registry lists arm denominators for the posted endpoint summaries, but those values alone do not establish the missing-data method or the population definition. The record also does not explain whether outcome-specific denominators differed for secondary measures.

These omissions limit assessment of how robust the estimates are to missingness, deviations from treatment, and analytical choices. They do not demonstrate that the analyses were improper; they mean that the relevant details cannot be evaluated from the registry record. The p-values and confidence intervals should be read as results of the analyses described, while recognizing that important implementation details are not reported.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (0.8%), cellulitis gangrenous (0.8%), sciatica (0.8%), drug hypersensitivity (0.8%), psychotic disorder (0.8%).

The registry reports serious adverse events for 7 participants in the tapering-dose group and 4 participants in the constant-dose group. The corresponding groups at risk were 131 and 128. Other adverse events are listed for 46 participants in the tapering group and 21 in the constant-dose group. Deaths are reported as 0 in each group.

The serious-event terms listed include pneumonia, cellulitis gangrenous, sciatica, drug hypersensitivity, psychotic disorder, and asthma, each reported as 0.8%. The registry record does not provide detailed event narratives or enough information to determine whether an event was judged related to study treatment. These figures describe reported events during the trial; they do not by themselves establish causation or quantify a comparative safety effect.

Counts should be read in the context of the stated group denominators and the study’s follow-up. Differences in counts alone are not a formal comparison, and the record does not report a statistical analysis of these safety outcomes. The posted serious adverse event figures are not a complete account of every possible harm or of longer-term safety beyond the recorded study period.

13. What the Result Does, and Does Not, Mean

The primary result describes an average difference in DAS28-ESR change over the period from baseline to Week 24 among participants with rheumatoid arthritis, stable low disease activity, and ongoing tocilizumab treatment. The estimated contrast is positive, and the score definition means that positive change represents worsening. The result therefore indicates that the measured average score change was less favorable in the prednisone-tapering group than in the constant-dose group during the reported follow-up.

This is a group-level statistical result. It does not mean that every participant in the tapering group worsened or that every participant in the constant-dose group improved. Individual outcomes can vary, and the confidence interval describes uncertainty in the estimated group contrast rather than the range of individual responses.

The result does not establish whether the observed contrast meets a threshold of clinical importance. The registry record does not report such a threshold. Nor does the result, on its own, resolve questions about outcomes after Week 24, other treatment strategies, participants without stable low disease activity, or people not receiving tocilizumab. Those questions are outside the primary comparison reported in the registry.

The secondary results provide additional information about treatment success and flares, but they do not erase the need to interpret each endpoint according to its definition and analysis. The record does not report a multiplicity plan or complete missing-data details, so the secondary findings warrant particular caution. Statistical evidence from this trial is not medical advice and should not be used as a stand-alone basis for an individual treatment decision.

14. Why This Trial Matters Statistically

This trial is statistically informative because it compares two prednisone strategies while the tocilizumab regimen is described as the same in both groups. That structure focuses the randomized comparison on tapering versus maintaining prednisone among participants with stable low disease activity while receiving tocilizumab. Randomization and double blinding, as described in the registry, are design features intended to support a fair comparison, although the record does not provide every operational detail needed to assess their implementation.

The primary result also illustrates why the endpoint scale and direction must be understood before interpreting a contrast. A positive DAS28-ESR change means worsening, so a positive between-group difference is not automatically a favorable result. The sponsor’s ANCOVA estimate, confidence interval, and p-value provide the central statistical comparison, while the arm estimates show the pattern underlying it.

At the same time, the trial highlights distinctions between primary and secondary evidence. Secondary endpoints can add context, but their differing definitions and multiple testing make them less decisive without a reported multiplicity plan. The registry’s planning illustrations also demonstrate a key design principle: sample-size requirements depend on the effect size selected for planning, and calculations based on an observed effect are not a substitute for the original design rationale.

Finally, the record is a reminder that a precise-looking estimate does not answer every question. The primary comparison concerns a specific population, treatment contrast, outcome, and follow-up period. Missing details about analysis populations, missing data, model specification, and multiplicity constrain how fully the result can be audited from the registry record alone.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The trial population is specifically described as participants with stable low disease activity receiving tocilizumab. The primary estimate therefore does not directly describe people with more active disease, people not receiving tocilizumab, or different prednisone strategies. The comparison is limited to the stated constant-dose and tapering regimens over 24 weeks.

The primary endpoint is a composite score based on joint counts, ESR, and a global assessment. A change in the composite can reflect movement in its components, but the primary result alone does not show which component contributed most. The registry record does not report component-level primary results or a threshold for clinical importance.

Important analytical details are not reported in the registry record, including covariates in the ANCOVA, analysis-population definitions, and the handling of missing observations and treatment deviations. The record also does not report a multiplicity strategy for secondary outcomes. These gaps limit assessment of sensitivity to modeling and missing-data choices, and reduce the strength of confirmatory interpretation for secondary findings.

The reported follow-up for the primary endpoint ends at Week 24. Longer-term disease activity, later flares, and sustained effects after the study period are not established by this endpoint. The registry’s adverse-event summaries give counts and selected serious-event terms, but do not provide detailed causal assessment or a statistical comparison. Finally, the record does not report the original sample-size rationale, so the planning illustrations based on observed effects should not be mistaken for the trial’s design justification.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants — NCT02573012.
• Registry record last updated 2019-11-01; status last verified 2019-10.
• Results first posted 2019-07-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed Phase 4 randomized, double-blind, parallel-group trial compared prednisone tapering with a constant prednisone dose among participants with rheumatoid arthritis and stable low disease activity receiving tocilizumab. The registry describes 314 enrolled participants and a 24-week treatment period.

The primary outcome was change in DAS28-ESR from baseline to Week 24. The sponsor-reported ANCOVA comparison was 0.613, with a 95% confidence interval from 0.346 to 0.879 and p = 0.001. Positive change indicates worsening on this scale, so the contrast favored the constant-dose strategy on the primary measure.

Secondary outcomes included treatment success and flare measures. The registry also reports adverse-event counts and selected serious-event terms. Multiplicity handling, missing-data procedures, and several model details are not reported in the registry record, limiting assessment of the full analysis context.